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Abstract: The mu opioid receptor (MOR) is the primary target for analgesia of endogenous
opioid peptides, alkaloids, synthetic small molecules with diverse scaffolds, and peptidomimetics.
Peptide-based opioids are viewed as potential analgesics with reduced side effects and have
received constant scientific interest over the years. This study focuses on three potent peptide
and peptidomimetic MOR agonists, DALDA, [Dmt1]DALDA, and KGOP01, and the prototypical
peptide MOR agonist DAMGO. We present the first molecular modeling study and structure–activity
relationships aided by in vitro assays and molecular docking of the opioid peptide analogues, in order
to gain insight into their mode of binding to the MOR. In vitro binding and functional assays revealed
the same rank order with KGOP01 > [Dmt1]DALDA > DAMGO > DALDA for both binding and
MOR activation. Using molecular docking at the MOR and three-dimensional interaction pattern
analysis, we have rationalized the experimental outcomes and highlighted key amino acid residues
responsible for agonist binding to the MOR. The Dmt (2′,6′-dimethyl-L-Tyr) moiety of [Dmt1]DALDA
and KGOP01 was found to represent the driving force for their high potency and agonist activity
at the MOR. These findings contribute to a deeper understanding of MOR function and flexible
peptide ligand–MOR interactions, that are of significant relevance for the future design of opioid
peptide-based analgesics.
Keywords: mu opioid receptor; opioid peptides and peptidomimetics; DAMGO; DALDA;
[Dmt1]DALDA; KGOP01; binding; molecular docking; structure-activity relationships
1. Introduction
Opioids are the mainstay in the management of moderate to severe pain, and remain the most
efficacious analgesics currently available [1]. The opioid receptors, mu (MOR), delta (DOR), and kappa
(KOR), are G protein-coupled receptors (GPCRs) and molecular targets for opioid analgesics [2],
that modulate nociception pathways in the central and peripheral nervous systems (CNS and PNS) [2–4].
Over the years, the MOR received a constant attention as the most important opioid receptor subtype
responsible for opioid-induced analgesia, but concomitantly is also most responsible for the unwanted
side effects (e.g., respiratory depression, constipation, sedation, dependence, and tolerance) of opioid
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analgesics [1,2]. All major clinically used opioid drugs, including morphine, oxycodone, and fentanyl,
are agonists at the MOR [1,5]. In the past decade, abuse and misuse of opioids became a significant
public health concern due to the huge rise in overdose morbidity and mortality [6,7]. In this view,
the development of effective and safer analgesics represents a key research goal for 21st century
analgesic drug discovery and pain medicine.
MOR mediates not only the analgesic effect of morphine, structurally related compounds,
and other opioid drugs, but it is also the endogenous target of naturally occurring peptides [3,4].
Under physiological conditions, the MOR is activated by β-endorphins, enkephalins, endomorphins,
and dermorphins, as endogenous neurotransmitters that have been extensively studied since their
discovery [8–10]. Although there is a strong evidence for their role in pain regulation and potential use
as analgesics, their poor enzymatic stability and difficulties in penetrating the blood–brain barrier (BBB)
after systemic administration have limited their clinical applicability [8–14]. Generation of potent,
stable peptidomimetics with improved pharmacodynamics and pharmacokinetics entails a systematic
understanding of the structure-activity relationships (SAR), where the function of key residues can be
determined using different strategies, such as amino acid substitution, deletion or addition of natural or
unnatural amino acids, conformational restriction through peptide main chain or side chain cyclization,
peptide bond replacement, or design of bi- or multifunctional peptide ligands [11–17]. A diversity of
opioid peptide-based analgesics with reduced adverse effects was made available through chemical
synthesis and appraised as prospective therapeutic agents or research tools [5,11,13–15,17].
Since the breakthrough of GPCR crystallization one decade ago, the understanding of the complex
biology of GPCR activation and signaling has dramatically increased [16–19]. Substantial advances
in structural biology of GPCRs were possible by means of innovative methodological and powerful
computational systems [20–22]. Due to its therapeutic relevance, the MOR is among the few GPCRs
determined in different activation states, with the first X-ray crystal structure of the murine MOR
published in 2012 in complex with the irreversible morphinan antagonist β-funaltrexamine (PDB ID:
4DKL) [23], and the 3D-structure in the active conformation reported in 2015, where the receptor was
co-crystallized with the morphinan agonist BU72 (PDB ID: 5C1M) [24]. Recently, the high resolution
cryo-electron microscopy (cryo-EM) structure of the MOR (PDB ID: 6DDF) bound to the agonist
peptide DAMGO (Figure 1) was reported [25], offering an important view on the structural features
that contribute to the Gi protein-coupling specificity of the MOR. The available crystal structures of the
MOR together with efficient computational methods (i.e., molecular docking and molecular dynamics
simulations) provide essential insights into binding modes of ligands to the receptor, with the gained
knowledge being successfully translated into the discovery of novel bioactive molecules [22,26,27].
Most of molecular modeling reports on the active and inactive structures of the MOR targeted small
molecules as ligands, with only few studies employing peptides, mostly DAMGO, as the prototypical
MOR selective synthetic analogue of the natural peptides enkephalin [25,28,29], endomorphin-2,
and dermorphin, as endogenous opioid ligands for the MOR [30,31].
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In this report, we have addressed for the first time a structure-based docking study at the active
conformation of the MOR of three peptide and peptidomimetic, potent MOR agonists, DALDA,
[Dmt1]DALDA, and KGOP01 (Figure 1). Merging experimental (in vitro assays) with computati nal
(in silico methods) approaches, we aimed to explain the molecular basis for their binding to the
MOR, in terms of understanding the structural correlations as well as interpreting the related
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SARs. The two peptides DALDA [32] and [Dmt1]DALDA [33] are synthetic analogues of the
naturally-occurring dermorphin, having high enzymatic stability due to the presence of D-Arg in
the second position of the peptide sequence (instead of D-Ala in dermorphin), and a modified Tyr1,
Dmt (2′,6′-dimethyl-L-Tyr), in [Dmt1]DALDA (Figure 1). While DALDA does not cross the BBB to a
significant extent, [Dmt1]DALDA was demonstrated to be able to pass the BBB to produce analgesia in
animals after systemic administration [13]. KGOP01 is a new tetrapeptide, CNS penetrant, and stable
analogue of [Dmt1]DALDA with two unnatural amino acids, 4-amino-tetrahydro-2-benzazepinone
(Aba) at position 3 and βAla at position 4 [34]. The rationale for the selection of these peptide
analogues is based on the numerous in vitro and in vivo studies that have established them as stable,
potent MOR agonists and effective analgesics in animal pain models with an interesting pharmacology,
as well as based on their value as leads in the development of new peptide ligands [13,34–43].
However, binding behavior of DALDA, [Dmt1]DALDA, and KGOP01 to their primary target, the
MOR, using computational approaches has not been investigated up to now. The findings of this
study provide structural insights into flexible peptide ligand–MOR interactions that are of significant
relevance for further understanding MOR function and pharmacology, and the future design of new
generation analgesics.
2. Results and Discussions
2.1. Comparison of In Vitro Binding and Activation Profiles of DALDA, [Dmt1]DALDA, and KGOP01 to
the MOR
We have initially performed a direct comparison of in vitro activity profiles of targeted opioid
peptide analogues, DALDA, [Dmt1]DALDA, and KGOP01 (Figure 1) at the human MOR, in terms of
receptor binding and activation. For comparison purposes, the opioid binding profile of DAMGO [44],
as the standard MOR agonist, is also presented. Whereas specific binding of DALDA and [Dmt1]DALDA
to the MOR in the rat brain has been reported previously [32], with both ligands showing high affinity
and selectivity for the MOR, in the present study the first data on binding affinity to the human MOR
is reported. Binding to the human MOR was evaluated using in vitro competitive radioligand binding
assays with membrane preparations from Chinese hamster ovary cells stably expressing the human
MOR (CHO-hMOR cells) and the specific MOR radioligand [3H]DAMGO, according to the published
procedures [43]. All three peptides displayed high capability to inhibit [3H]DAMGO binding to the
human MOR in a concentration-dependent manner (Figure 2A), with binding affinities (as Ki values)
in the low nanomolar to subnanomolar range (Table 1).
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The high binding affinities to the human recombinant MOR expressed in CHO cells showed by
DALDA and [Dmt1]DALDA confirms earlier data at the rat MOR in the brain tissue (Ki values of
1.69 nM for DALDA, and 0.143 nM for [Dmt1]DALDA) [32]. As shown in Table 1, replacement of the
Tyr1 residue in DALDA with Dmt1 in [Dmt1]DALDA led to a significant increase (27-fold) in binding
affinity to the human MOR, an observation that is in good agreement with findings at the rat MOR [32].
Additionally, exchanging Phe3-Lys4 residues in [Dmt1]DALDA with an unnatural, uncommon amino
acid, respectively, in the Aba3-βAla4 sequence lead to in a new analogue, KGOP01 [34], which exhibited
a further increase (ca. 2-fold) in the MOR affinity than [Dmt1]DALDA, and a 13-fold better MOR
affinity than DAMGO (Table 1, Figure 2A).
Table 1. In vitro binding and agonist activity of opioid peptide analogues at the human MOR.
Opioid Peptide
Binding Affinity a Agonist Activity b
Ki (nM) EC50 (nM) % stim.
DAMGO 1.46 ± 0.37 18.1 ± 2.0 100
DALDA 6.36 ± 0.24 149 ± 28 92 ± 2
[Dmt1]DALDA 0.23 ± 0.02 0.51 ± 0.06 90 ± 4
KGOP01 0.11 ± 0.05 0.10 ± 0.02 99 ± 6
a Determined in competitive radioligand binding assays using membrane from CHO expressing the human MOR
(CHO-hMOR). b Determined in the [35S]GTPγS binding assay using CHO-hMOR cell membranes. Percentage
stimulation (% stim.) relative to DAMGO (reference MOR full agonist). Values are means± SEM (n = 3-4 independent
experiments).
Next, we have compared in vitro functional activities of DALDA, [Dmt1]DALDA and KGOP01 at
the human MOR in the guanosine-5′-O-(3-[35S]thio)-triphosphate ([35S]GTPγS) binding assay using
membranes from CHO cells stably expressing the human MOR, performed as described [43]. All tested
peptides produced a concentration-dependent increase in the [35S]GTPγS binding with different levels
of potencies (Figure 2B). Whereas DALDA and [Dmt1]DALDA showed full efficacy at the MOR,
[Dmt1]DALDA had a considerable increased (292-fold) in agonist potency than DALDA in inducing
MOR-mediated G protein activation (Table 1). Additionally, [Dmt1]DALDA had higher agonist potency
(35-fold) than that of DAMGO. Previous in vitro bioassays using guinea-pig ileum (GPI) preparations
established [Dmt1]DALDA as a more potent MOR agonist (180-fold) than DALDA [32]. Further,
an enhanced MOR agonist potency by 5-fold was measured in the present study for KGOP01 as
compared to [Dmt1]DALDA in the [35S]GTPγS binding assay (Table 1). The potent MOR agonist profile
of KGOP01 was established previously in the GPI bioassay (IC50 = 0.8 nM) [34] and cAMP accumulation
assay with HEK293 cells expressing the human MOR (EC50 = 0.204 nM) [42]. The outcomes derived
from functional assays correlate well with the results obtained in binding studies at the MOR and
structural features of investigated peptide analogues, where [Dmt1]DALDA and KGOP01 show a
better in vitro profile than DALDA, with KGOP01 being the most potent MOR agonist of the series.
2.2. In Silico Investigation of DALDA, [Dmt1]DALDA, and KGOP01 Binding to the MOR
The observed differences in the in vitro activity profiles of DALDA, [Dmt1]DALDA, and KGOP01
(Table 1) encouraged in silico investigations of their binding modes at the MOR. The recently published
crystal structure of the active conformation of the MOR (PDB ID: 5C1M; resolution: 2.1 Å) [24]
provides the structural basis for understanding important aspects of MOR pharmacology and its
function [22,24,45]. In order to examine possible binding conformations of the targeted peptide
analogues to the MOR, docking experiments were performed using GOLD [46], and LigandScout [47]
was used to analyze differences in receptor–ligand interactions. We used the numbering scheme from
the PDB together with Ballosteros–Weinstein nomenclature.
Since the available crystal structure of the active MOR (PDB ID: 5C1M) [24] represents the murine
receptor, a structural model of the human MOR was built by in silico mutations of differing residues.
Interestingly, six out of seven differing amino acid residues are located in the extracellular region.
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The high similarity in the receptor core region and the intracellular side suggests a conserved receptor
activation mechanism, but potential differences for ligand recognition (Figure 3). However, only one
of these residues turned out to directly point to the ligand binding site. Instead of a histidine at
position 54 in the murine MOR, the human receptor has an aspartic acid at this position. Notable,
the recently reported cryo-EM structure of the MOR (PDB ID: 6DDF; resolution: 3.5 Å) [25] bound to
the agonist peptide DAMGO misses the N-terminal region and unveils a binding mode for DAMGO,
which is not compatible with the previous crystal structure [24] (Figure 4), indicating that DAMGO
might bind differently in the truncated vs. untruncated receptor. Due to the fact that the cryo-EM
structure presents the MOR bound to DAMGO, this structure was subsequently used for binding mode
investigations of DALDA, [Dmt1]DALDA, and KGOP01, with the same in silico mutations as in the
abovementioned structural model of the human MOR. The discrepancies between the crystal structure
and the cryo-EM structure with regard to the N-terminus suggests an important, but different role in
binding of non-peptide ligands, such as morphinan-based agonists and peptide ligands. We would
like to note that binding mode predictions are always of hypothetic nature and in this specific case
the reliability of our proposed interaction pattern strongly depends on the receptor region. Whereas
the C-terminal parts of the studied peptides, located in the receptor core region are more reliable,
the missing structural information for the N-terminus of the receptor makes the binding orientations
of the N-terminal parts of the studied peptides and resulting interactions more speculative.
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Docking of DAMGO, DALDA, [Dmt1]DALDA, and KGOP01 to the structural model of the human
MOR (PDB ID: 6DDF) resulted in comparable binding orientations for the four peptides (Figure 5).
Several receptor–ligand interactions were observed in all complexes (Figure 6), and an overview of
detected receptor–ligand interactions is presented in Figure 7. Due to missing information on the
role of the receptor’s N-terminus for ligand binding and the high flexibility of the peptide ligands,
the interactions with the extracellular loop regions are more speculative than the interactions within
the inner core region. As expected, D1473.32 forms a charge interaction with the primary amine of
the tyrosine (in DAMGO and DALDA) or the Dmt (in [Dmt1]DALDA and KGOP01). Additionally,
this primary amine of the tyrosine of DALDA and [Dmt1]DALDA forms a π–cation interaction with
Y1483.33. The central role of D1473.32 and Y1483.33 for binding of DAMGO, morphine and morphinan
ligands, and other small molecules to the MOR is well-recognized [23–28,48]. The phenol moieties of
all ligands are pointing towards I2966.51 and form a hydrogen bond except for DAMGO. In theory,
the phenol moieties could also form hydrogen bonds to water molecules as observed in the MOR crystal
Molecules 2020, 25, 2087 6 of 12
structure (PDB ID: 5C1M), but the role of water-mediated interaction networks for peptide ligands is
still not clear. The phenyl rings of the phenylalanine (in DAMGO, DALDA, and [Dmt1]DALDA) fill a
hydrophobic pocket that comprises the aliphatic chain of I1443.29 residues. While the Aba moiety of
KGOP01 only reaches I1443.29, it also makes KGOP01 more rigid and thereby allows for a potentially
highly favorable hydrogen bond with K3036.58. Interestingly, the methyl group of the alanine of
DAMGO shows unique lipophilic contacts with W3187.34 and I3227.38 residues, which could not be
observed for the other peptides. In comparison, DAMGO and KGOP01 are more similar in terms of
their hydrogen bonding pattern including T218ECL2 and K3036.58. Further, DALDA and [Dmt1]DALDA
only differ in the additional lipophilic contact of [Dmt1]DALDA with Y3267.42. Overall, the four
targeted opioid peptides show comparable binding modes to the MOR. The tyrosine/Dmt ring of
all four peptides shows lipophilic contacts with M1513.36, I2966.51, and V3006.55 residues. The two
methyl groups of the Dmt moiety in [Dmt1]DALDA and KGOP01 show additional lipophilic contacts
with Y1483.33 and Y3267.42 residues, which might lower the entropic penalty upon binding (Figure 8).
The latter rigidification effect might also strengthen the hydrogen bond with I2966.51 residue (Figure 6).
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Figure 4. Superimposition of the crystal structure of the MOR (PDB ID: 5C1M) with co-crystallized
BU72 (grey), and the recently available cryo-EM structure (PDB ID: 6DDF) with bound DAMGO (blue)
in a transmembrane (A) and extracellular view (B). The close-up view on DAMGO (blue surface) in the
binding site (C) unveils a sterical clash (circle) of the peptide with the N-terminus resolved in the active
crystal structure.
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3. Materials and Methods
3.1. Chemicals and Materials
Cell culture media and supplements were obtained from Sigma-Aldrich Chemicals (St. Louis, MO,
USA). Radioligands [3H]DAMGO (50 Ci/mmol) and [35S]GTPγS (1250 Ci/mmol) were purchased from
PerkinElmer (Boston, MA, USA). DAMGO, unlabeled GTPγS, and guanosine diphosphate (GDP) were
obtained from Sigma-Aldrich Chemicals (St. Louis, MO, USA). All other chemicals were of analytical
grade and obtained from standard commercial sources.
3.2. Peptide and Peptidomimetic Ligands
DALDA [32], [Dmt1]DALDA [33], and KGOP01 [34] were synthesized as described previously [34],
with purities >98%. DAMGO was obtained from Sigma-Aldrich Chemicals (St. Louis, MO, USA).
Test peptides were prepared as 1 mM stocks in water, and further diluted to working concentrations in
the appropriate medium.
3.3. Cell Culture
CHO cells stably expressing the human MOR were kindly provided by Dr. Lawrence Toll (SRI
International, Menlo Park, CA, USA). The CHO-hMOR cell line was grown in Dulbecco’s Minimal
Essential Medium (DMEM)/Ham’s F-12 medium supplemented with fetal bovine serum (FBS, 10%),
penicillin/streptomycin (0.1%), L-glutamine (2 mM), and geneticin (400 µg/mL). Cells were maintained
at 37 ◦C in 5% CO2 humidified air.
3.4. Competitive Radioligand Binding Assays
Binding assays were conducted on human MOR stably transfected into CHO cells (CHO-hMOR)
according to the published procedure [43]. Cell membranes were prepared as described previously,
and stored at−80 ◦C until use [43]. Protein concentration of cell membrane preparations was determined
by the method of Bradford using bovine serum albumin as the standard [49]. Cell membranes (15–20 µg)
were incubated in 50 mM Tris-HCl buffer (pH 7.4) with [3H]DAMGO (1 nM) and various concentrations
of test peptides in a final volume of 1 mL, for 60 min at 25 ◦C. Non-specific binding was determined
using 10 µM of unlabeled DAMGO. After incubation, reactions were terminated by rapid filtration
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through Whatman glass GF/C fiber filters. Filters were washed three times with 5 mL of ice-cold
50 mM Tris-HCl buffer (pH 7.4) using a Brandel M24R cell harvester (Gaithersburg, MD, USA).
Radioactivity retained on the filters was counted by liquid scintillation counting using a Beckman
Coulter LS6500 (Beckman Coulter Inc., Fullerton, CA, USA). The inhibitory constant (Ki, in nM)
values were calculated from the competition binding curves by nonlinear regression analysis and
the Cheng–Prusoff equation [50]. All experiments were performed in duplicate and repeated at least
three times.
3.5. [35S]GTPγS Binding Assays
Binding of [35S]GTPγS to membranes from CHO cells stably expressing the human
MOR(CHO-hMOR) was conducted according to the published procedure [43]. Cell membranes
(5-10 µg) in 20 mM HEPES, 10 mM MgCl2, and 100 mM NaCl, pH 7.4 were incubated with 0.05 nM
[35S]GTPγS, 10 µM GDP and various concentrations of test peptides in a final volume of 1 mL,
for 60 min at 25◦C. Non-specific binding was determined using 10 µM GTPγS, and the basal binding
was determined in the absence of test ligand. Samples are filtered over glass Whatman glass GF/B fiber
filters and counted as described for binding assays. In each individual experiment, the increase in
[35S]GTPγS binding produced by the test peptides were normalized to the maximal stimulation of the
reference full MOR agonist, DAMGO and nonlinear regression performed on each individual curve
were averaged to yield potency (EC50, in nM) and efficacy (as % stim.) values. All experiments were
performed in duplicate and repeated at least three times.
3.6. Data Analysis
Experimental data were analyzed and graphically processed using the GraphPad Prism 5.0
Software (GraphPad Prism Software Inc., San Diego, CA, USA), and are presented as means ± SEM.
3.7. Molecular Modeling
The structure of the human MOR was remodeled based on the crystal structure of the murine MOR
(PDB ID: 5C1M) [24] by using the mutation tool of Molecular Operating Environment (MOE, 2019.0101;
Chemical Computing Group Inc., Montreal, QC, Canada) with subsequent sidechain optimization.
Complementary, the cryo-EM structure of the MOR with bound DAMGO (PDB ID: 6DDF) [25] was
used. All receptor-ligand docking experiments were performed with the CCDCs software GOLD
version 5.7.0 [46]. Water molecules and ligands were removed. Assignment of protonation states and
protein preparation were performed using Protonate3D [51] (implemented in MOE 2019.1, Chemical
Computing Group, Montreal, QC, Canada). All residues of the inner receptor core region and the
C-terminal domain were defined as potential binding site (12 Å around the γ-carbon atom of D147;
PDB ID: 6DDF) [25]. For receptor-ligand docking, default settings were applied and GoldScore served
as primary scoring function with DAMGO as reference ligand. All obtained docking poses and
receptor–ligand interactions were analyzed using LigandScout 4.4 [47] using a 3D-pharmacophore
approach [52].
4. Conclusions
Given the essential clinical role of the MOR in mediating pain inhibition and other physiological
activities, with endogenous peptides as natural agonists of the MOR, a basic understanding of the
binding mechanism of opioid peptides to the MOR is required for their further development as
potential analgesics and drugs for pain treatment and other human disorders. The peptidic nature
of endogenous MOR agonists provides a variety of modification possibilities to design specific and
stable MOR agonists. In this study, we have reported on a set of peptide analogues, DAMGO, DALDA,
[Dmt1]DALDA, and KGOP01, for which in silico binding modes and in vitro activities at the MOR were
correlated. The present results evidence the consequence of the modified Tyr1, Dmt, in [Dmt1]DALDA
and KGOP01 on the pharmacological profile with molecular docking studies offering a structural
Molecules 2020, 25, 2087 10 of 12
basis for the observed MOR activities. In vitro receptor binding and functional assays revealed the
same rank order with KGOP01 > [Dmt1]DALDA > DAMGO > DALDA for both binding and MOR
activation. In silico binding mode investigations indicated the important contribution of the Dmt
moiety for binding and MOR activation, specifically, with the two methyl groups of the Dmt moiety
in [Dmt1]DALDA and KGOP01 showing additional lipophilic contacts with Y1483.33 and Y3267.42
residues. Generally, the limited CNS penetration of peptides often impairs their development as
therapeutics. Furthermore, the feasibility of peptides for clinical application is much precluded by
their enzymatic degradation. DALDA, [Dmt1]DALDA, and KGOP01 have high stability against
enzymatic degradation, due to the presence of certain structural modifications, i.e., unnatural and
synthetic amino acids. While DALDA does not cross the BBB, the [Dmt1]DALDA and KGOP01 can
enter the CNS [13,42]. The gained knowledge from this study on which molecular interactions with
the MOR these opioid peptides share and distinguish them, with Y1483.33 and Y3267.42 sites being
of significance, may also help to understand the differences in the pharmacokinetics between these
peptides. Our findings offer structural insights into flexible peptide ligand–MOR interactions that are
important for further understanding of MOR function and pharmacology, and the future design of
peptide-based analgesics.
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